Medical Oncology

Immune Checkpoint Inhibitor

Questions discussed in this category

Would you use immunotherapy in patients with HIV and a positive viral load?

1 Answer available

Would you offer adjuvant AC + pembrolizumab for a triple negative breast cancer patient whose tumor progressed on carboplatin + paclitaxel + pembrolizumab on KEYNOTE-522 and required urgent surgery (ypT3 ypN0)?

If not, would you lean towards adjuvant capecitabine?

1 Answer available

Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?

As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...

1 Answer available

In a patient with HER2+ advanced endometrial cancer, do you include IO(+/- olaparib) in their treatment regimen, or only trastuzumab in addition to carboplatin/paclitaxel?

Does your decision depend on MMR status? Would you use the same approach for neoadjuvant treatment?In light of relevant trials including RUBY, GY018, ...

3 Answers available

Would you recommend adjuvant chemo+IO +/- olaparib for patients with occult stage III disease identified after staging surgery with no measurable residual disease?

DUO-E, GY-018, and RUBY included patients with stage III and IV endometrial cancer WITH measurable disease.Would your decision change based on the mis...

4 Answers available

In patients with advanced endometrial cancer who you plan to treat with chemotherapy + immunotherapy (per GY018 or RUBY), how and when do you utilize adjuvant EBRT and/or brachytherapy?

Does the presence of parametrial or cervical involvement impact your decision? How do you sequence treatment modalities?

3 Answers available

How do you schedule IV/PO Dexamethasone if giving immunotherapy concurrently with chemotherapy in patients with NSCLC?

1 Answer available

Papers discussed in this category

N Engl J Med, 2023 Mar 27

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

N Engl J Med, 2023 Mar 27

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.

Journal of clinical oncology : Official Journal of the American Society of Clinical Oncology, 2023 Oct 21

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.

Translational cancer research, 2021 May

Combination radiation and immunotherapy in gynecologic malignancies-a comprehensive review.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Lancet (London, England), 2023 Oct 20

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 23

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.

The New England journal of medicine, 2018-05-31

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2018-11-22

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

N. Engl. J. Med.,

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

J Clin Oncol, 2023 Jul 20

Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

Journal for immunotherapy of cancer, 2024 Aug 22

Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Oct 02

Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.

Cancer, 2023 Nov 14

Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study.

Related Topics in Medical Oncology